Latest Breaking News On - Esperion therapeutics daily - Page 5 : comparemela.com

Esperion Therapeutics, Inc (NASDAQ:ESPR) Given Consensus Recommendation of Hold by Brokerages

Esperion Therapeutics, Inc (NASDAQ:ESPR) Given Consensus Recommendation of Hold by Brokerages
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesEsperion therapeutics company profilePrincipal financial group incProshare advisorsYork mellon corpEsperion therapeutics incMetlife investment managementNeedham companyEsperion therapeuticsGet free reportFinancial groupShare advisorsNew york mellon corpLife investment managementRhumbline advisersGet free

Esperion Therapeutics, Inc (NASDAQ:ESPR) Receives Consensus Rating of Hold from Brokerages

Esperion Therapeutics, Inc (NASDAQ:ESPR) Receives Consensus Rating of Hold from Brokerages
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesEsperion therapeutics incNeedham companyPortfolio partnersSei investments coSimplicity solutionsEsperion therapeutics company profileChicago partners investment groupTower research capitalEsperion therapeuticsGet free reportPartners investment groupResearch capitalGet freeEsperion therapeutics daily

HC Wainwright Reaffirms Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)

HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Esperion Therapeutics’ FY2026 earnings at $2.50 EPS, FY2027 earnings at […]

United statesEsperion therapeutics incRoyal bankPrelude capital managementBarclays plcNeedham companyCapital partnersVanguard group incEsperion therapeuticsFree reportEsperion therapeuticGet free reportCapital managementEsperion therapeutics dailyNasdaq esprReiterated rating

Esperion Therapeutics Target of Unusually High Options Trading (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) was the recipient of some unusual options trading on Monday. Investors acquired 11,472 call options on the stock. This represents an increase of approximately 223% compared to the average daily volume of 3,554 call options. Wall Street Analyst Weigh In ESPR has been the subject of several […]

United statesEsperion therapeutics incEsperion therapeutics company profileNeedham companyVanguard group incWasatch advisors incArmistice capitalEsperion therapeuticsGet free reportEsperion therapeutics dailyNasdaq espr

Esperion Therapeutics (NASDAQ:ESPR) Sees Unusually-High Trading Volume

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 2,385,252 shares were traded during trading, a decline of 61% from the previous session’s volume of 6,092,242 shares.The stock last traded at $2.73 and had previously closed at $2.62. Analyst Ratings Changes ESPR has been the subject […]

United statesEsperion therapeutics company profileArmistice capitalWasatch advisors incNeedham companyEsperion therapeutics incVanguard group incEsperion therapeuticsGet free reportEsperion therapeutics daily